NEU 2.37% $19.39 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-149

  1. 6,422 Posts.
    lightbulb Created with Sketch. 688
    Just going back to your earlier points within this post.

    You and I have danced around autism for some time. My ears pricked initially when we were granted a patent in Israel.

    I'd like to know (from anyone). Has anyone ever gone to the FDA and requested that four phase 2 trials be combined so that one phase 3 trial can be initiated to cover all of the spectrums?

    Because if that was possible. Thats my go to. 1 trial (self funded) that covers 4 spectrums.
    If you pass, these talks of $200 become real.

    If it cant be done, then let's sell and move on. We aren't funding four Ph 3 trials. We just aren't.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.